Indian stocks are poised for a favorable period. Falling crude oil prices and a strengthening rupee offer support. Macroeconomic conditions...

ICICI Prudential's Mittul Kalawadia advises caution on current market valuations. He notes that future growth is already factored into stoc...

India's labour productivity gap with China has widened significantly since 2000, despite strong economic growth. The country has yet to ach...

Pharma industry officials say the revised Schedule M regulations could require Rs 10-15 crore per facility in upgrades, while talent shorta...

Indian companies show strong recovery. Over 50 firms moved from losses to profits in the March quarter. This turnaround happened despite ma...

Government health spending has risen, leading to a significant drop in out-of-pocket health expenses. This decline, from 64.2% in 2013-14 t...

Sun Pharma reported strong revenue and profit growth in the March quarter, but EBITDA margins faced pressure from increased investments and...

Market expert Sunil Subramaniam advised caution amid geopolitical uncertainty and rising input costs, while favouring consumer durables, ca...

Sun Pharma is expected to post double-digit revenue growth in Q4FY26, driven by strong performance across speciality drugs, domestic formul...

Bio Medica Laboratories' initial public offering begins subscription on Thursday. The company plans to raise Rs 52.43 crore through its IPO...

India's manufacturing growth is hampered by low R&D spending, currently at 0.6% of GDP, a report highlights. To boost its manufacturing sha...

Investors are increasingly betting that “China is back” as the economy rebounds from years of deflation, helped by strong manufacturing, ex...

Logistics firm Delhivery has promoted six senior executives to C-suite positions. These appointments support the company's expansion across...

A CNI InfoXchange study projects the Nifty could surpass 42,000 by 2028 if sustained foreign investor inflows return. The report highlights...

India’s cancer treatment landscape is seeing a shift as lower-cost immunotherapy drugs developed in China and marketed through Indian partn...

India's primary market is set for a busy week with two SME IPOs. RFBL Flexi Pack and Goldline Pharmaceutical will open for subscription on ...

As global markets prioritise quality and regulatory trust, India’s pharma sector is recalibrating beyond its traditional cost advantage.